Clinical efficacy of Arbidol (umifenovir) in the therapy of influenza in adults: Preliminary results of the multicenter double-blind randomized placebo-controlled study ARBITR

Terapevticheskii Arkhiv

Volumn 87, Issue 1, 2015, Pages 88-96

  Kiselev, O I ^a   Maleev, V V ^b   Deeva, E G ^a   Leneva, I A ^c   Selkova, E P ^d   Osipova, E A ^d   Obukhov, A A ^e   Nadorov, S A ^f   Kulikova, E V ^f  

^a N N BLOKHIN NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY   (Russian Federation)

^b CENTRAL RESEARCH INSTITUTE OF EPIDEMIOLOGY   (Russian Federation)

^c MECHNIKOV RESEARCH INSTITUTE FOR VACCINES AND SERA   (Russian Federation)

^d GN Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology   (Russian Federation)

^e JSC OTCpharm   (Russian Federation)

^f JSC Pharmstandart   (Russian Federation)

Author keywords

Arbidol (umifenovir); Clinical efficacy; Influenza; Multicenter double blind randomized placebo controlled ARBITR study

Indexed keywords

ANTIVIRUS AGENT; ARBIDOL; INDOLE DERIVATIVE; VIRUS RNA;

ADOLESCENT; ADULT; AGED; BLOOD; CLINICAL TRIAL; COMMON COLD; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INFLUENZA, HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RUSSIAN FEDERATION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; COMMON COLD; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDOLES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; RNA, VIRAL; RUSSIA; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84928473452     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: 10.17116/terarkh201587188-96     Document Type: Article

References (27)

1. The world health report 2002 - Reducing Risks, Promoting Healthy Life. World Health Organization 2002: 186, 192.
2. Jefferson T., Di Pietrantonj C., Rivetti A. et al. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2010; 7: CD001269.
3. Rothberg M.B., Haessler S.D., Brown R.B. Complications of viral influenza. Am J Med 2008; 121 (4): 258-264.
4. WHO Guidelines on the Use of Vaccines and Antivirals during Influenza Pandemics WHO/CDS/CSR/RMD/2004.8.
5. Fiore A.E., Shay D.K., Broder K. et al.; Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep 2008; 57 (RR-7): 1-60.
6. Hayden F.G., Osterhaus A.D., Treanor J.J. et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl J Med 1997; 337: 874-880.
7. Monto A.S., Fleming D.M., Henry D. et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J Infect Dis 1999; 180: 254-261.
8. Nicholson K.G., Aoki F.Y., Osterhaus A.D. et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000; 355: 1845-1850.
9. Treanor J.J., Hayden F.G., Vrooman P.S. et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 2000; 283: 1016-1024.
10. Whitley R.J., Hayden F.G., Reisinger K.S. et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001; 20: 127-133.
11. Hedrick J.A., Barzilai A., Behre U. et al. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. Pediatr Infect Dis J 2000; 19: 410-417.
12. Lalezari J., Campion K., Keene O. et al. Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials. Arch Intern Med 2001; 161: 212-217.
13. Monto A.S., Webster A., Keene O. Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis. J Antimicrob Chemother 1999; 44 (Suppl B): 23-29.
14. MIST (Management of Influenza in the Southern Hemisphere Trialists). Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Lancet 1998; 352: 1877-1881.
15. Hayden F.G. Newer influenza antivirals, biotherapeutics and combinations. Influenza Other Respir Viruses 2013; 7 (Suppl 1): 63-75.
16. Leneva I.A., Russell R.J., Boriskin Y.S., Hay A.J. Characteristics of Arbidol-Resistant Mutants of Influenza Virus: Implications for the Mechanism of Anti-Influenza Action of Arbidol. Antiviral Res 2009; 81: 132-140.
17. Boriskin Y., Leneva I., Pecheur E., Polyak S. Arbidol: a broadspectrum antiviral compound that bloks viral fusion. Curr Med Chem 2008; 15: 997-1005.
18. Delogu I., Pastorino B., Baronti C. et al. In vitro antiviral activity of arbidol against Chikungunya virus and characteristics of a selected resistant mutant. Antiviral Res 2011; 90 (3): 99-107.
19. Nasser Z.H., Swaminathan K., Müller P., Downard K.M. Inhibition of influenza hemagglutinin with the antiviral inhibitor arbidol using a proteomics based approach and mass spectrometry. Antiviral Res 2013; 100 (2): 399-406.
20. Brancato V., Peduto A., Wharton S. et al. Design of inhibitors of influenza virus membrane fusion: synthesis, structure-activity relationship and in vitro antiviral activity of a novel indole series. Antiviral Res 2013; 99 (2): 125-135.
21. Brooks M.J., Burtseva E.I., Ellery P.J. et al. Antiviral activity of arbidol, a broad-spectrum drug for use against respiratory viruses, varies according to test conditions. J Med Virol 2012; 84 (1): 170-181.
22. Shi L., Xiong H., He J. et al. Antiviral activity of arbidol against influenza A virus, respiratory syncytial virus, rhinovirus, coxsackie virus and adenovirus in vitro and in vivo. Arch Virol 2007; 152: 1447.
23. Wang M.Z., Cai B.Q., Li L.Y. et al. Efficacy and safety of arbidol in treatment of naturally acquired influenza. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2004; 26 (3): 289-293.
24. Hong-bo L. I. U., Wen-xiu Q.U., Sheng-qi L.I. Multicenter randomized double blind parallel clinical trial of arbidol hydrochloride tablet. Chinese J Clin Pharmacol 2006; 6: 403-405.
25. Suess T., Remschmidt C., Schink S.B. et al. Comparison of shedding characteristics of seasonal influenza virus (sub)types and influenza A(H1N1)pdm09; Germany, 2007-2011. PLoS One 2012; 7 (12): e51653.
26. Carrat F., Vergu E., Ferguson N. et al. Time Lines of Infection and Disease in Human Influenza: A Review of Volunteer Challenge Studies. Am J Epidemiol 2008; 167 (7): 775-785.
27. ATC/DDD Classification WHO. Drug Information 2014; 28 (2): 209.